These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 27013871)
1. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Miravitlles M; Montero-Caballero J; Richard F; Santos S; Garcia-Rivero JL; Ortega F; Ribera X Int J Chron Obstruct Pulmon Dis; 2016; 11():407-15. PubMed ID: 27013871 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the preference, satisfaction and correct use of Breezhaler Oliveira MVC; Pizzichini E; da Costa CH; Fritscher CC; Vianna EO; Teixeira PJZ; Stirbulov R; Rabahi MF; Pinho NC Respir Med; 2018 Nov; 144():61-67. PubMed ID: 30366585 [TBL] [Abstract][Full Text] [Related]
3. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Chapman KR; Fogarty CM; Peckitt C; Lassen C; Jadayel D; Dederichs J; Dalvi M; Kramer B Int J Chron Obstruct Pulmon Dis; 2011; 6():353-63. PubMed ID: 21760722 [TBL] [Abstract][Full Text] [Related]
4. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Ohno T; Wada S; Hanada S; Sawaguchi H; Muraki M; Tohda Y Int J Chron Obstruct Pulmon Dis; 2014; 9():107-14. PubMed ID: 24489464 [TBL] [Abstract][Full Text] [Related]
6. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? Dahl R; Kaplan A BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909 [TBL] [Abstract][Full Text] [Related]
8. Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. Davis KH; Su J; González JM; Trudeau JJ; Nelson LM; Hauber B; Hollis KA Health Qual Life Outcomes; 2017 Oct; 15(1):201. PubMed ID: 29037248 [TBL] [Abstract][Full Text] [Related]
9. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey. Price D; Keininger DL; Viswanad B; Gasser M; Walda S; Gutzwiller FS Int J Chron Obstruct Pulmon Dis; 2018; 13():695-702. PubMed ID: 29520137 [TBL] [Abstract][Full Text] [Related]
10. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Hodder R; Price D Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356 [TBL] [Abstract][Full Text] [Related]
11. COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study. Ferguson GT; Ghafouri M; Dai L; Dunn LJ Int J Chron Obstruct Pulmon Dis; 2013; 8():139-50. PubMed ID: 23658479 [TBL] [Abstract][Full Text] [Related]
12. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742 [TBL] [Abstract][Full Text] [Related]
13. The Respimat Soft Mist Inhaler, a Novel Inhaled Drug Delivery Device. Perriello EA; Sobieraj DM Conn Med; 2016; 80(6):359-64. PubMed ID: 27509644 [TBL] [Abstract][Full Text] [Related]
14. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177 [TBL] [Abstract][Full Text] [Related]
15. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Molimard M; Raherison C; Lignot S; Balestra A; Lamarque S; Chartier A; Droz-Perroteau C; Lassalle R; Moore N; Girodet PO Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28182569 [TBL] [Abstract][Full Text] [Related]
16. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941 [TBL] [Abstract][Full Text] [Related]
17. Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care. Ding B; Small M; Scheffel G; Holmgren U Int J Chron Obstruct Pulmon Dis; 2018; 13():927-936. PubMed ID: 29588581 [TBL] [Abstract][Full Text] [Related]
18. Assessment of Patient Experiences with Respimat Taube C; Bayer V; Zehendner CM; Valipour A Pulm Ther; 2020 Dec; 6(2):371-380. PubMed ID: 32857327 [TBL] [Abstract][Full Text] [Related]
19. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD]. Henriet AC; Marchand-Adam S; Mankikian J; Diot P Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393 [TBL] [Abstract][Full Text] [Related]
20. Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. Pascual S; Feimer J; De Soyza A; Sauleda Roig J; Haughney J; Padullés L; Seoane B; Rekeda L; Ribera A; Chrystyn H NPJ Prim Care Respir Med; 2015 Apr; 25():15018. PubMed ID: 25927321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]